Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

• DOI: 10.1111/cei.12196
• Publication Date: 2013-08-29T12:12:28Z
• Authors: A C Chan; P Neeson; E Leeansyah; K Tainton; H Quach; H M Prince; S J Harrison; D I Godfrey; D Ritchie; S P Berzins
• Keywords: Cell therapy

Summary The causes of multiple myeloma (MM) remain obscure and there are few known risk factors; however, natural killer T (NKT) cell abnormalities have been reported in patients with MM, therapeutic targeting NKT cells is promoted as a potential treatment. We characterized defects treated untreated MM determined the impact lenalidomide therapy on pool. Lenalidomide an immunomodulatory drug co-stimulatory effects vitro approved treatment for although its mode action that context not well defined. find relapsed/progressive had marked deficiency numbers. In contrast, newly diagnosed relatively normal frequency function prior to treatment, specific emerged after high-dose melphalan autologous stem transplantation (ASCT) regimen. This also impacted NK conventional cells, but recovery was considerably delayed, resulting prolonged, treatment-induced deficit. Longitudinal analysis individual revealed no in-vivo numbers or cytokine production, either induction therapy, maintenance following ASCT, indicating clinical benefits this setting independent modulation.